Claims-Based Survival Models Have Potential to Aid Prostate Cancer Decision Making
“Most men with early-stage prostate cancer will die with their disease, not from their disease,” Dr Murphy said.
Latest Features
LATEST ARTICLES
Unlocking the Potential of Biosimilars in Community Oncology
Full adoption of biosimilars will require proper provider and patient education, payer coverage navigation support, and streamlined workflows.
Can Patient-Derived Organoids Help Oncologists Make Treatment Decisions?
Organoids created from tumor samples have been revolutionizing laboratory research, but they also may begin helping oncologists decide on treatment regimens for patients.
Immunosuppression Tied to Poor Outcomes in Multiple Cutaneous SCC
Investigators estimated the effects of immunosuppression on poor outcomes in multiple cutaneous squamous cell carcinoma.
Intravenous Busulfan Plus Melphalan vs Melphalan Alone as a Conditioning Regimen in Multiple Myeloma: Is There a Difference?
There appears to be accumulating evidence to support the routine use of busulfan plus melphalan as a conditioning regimen.
Nivolumab Plus Ipilimumab Proven Cost Effective in Advanced RCC
An analysis of the immunotherapy combination compared with sunitinib placed the combo on the high end of willingness-to-pay thresholds for cancer drugs.
Data Mining to Develop Mutation-Specific Treatments in Acute Myeloid Leukemia
Integrating mutation-specific data across repositories and portals may lead to novel therapeutically actionable insights for acute myeloid leukemia.
The Hidden Privilege of Reference Genomes
Researchers establish a Chinese-specific BRCA database to cover nearly all of the BRCA variation information currently known across this population.
Understanding the Limitations of CAR-T Cell Therapies
CAR-T’s inability to induce durable remissions in many patients is a barrier to the success of these adoptive cell therapies—but solutions are under way.
Can Time to Treatment Initiation Be Effectively Reduced?
With the rising rates of cancer diagnosis and increasing cost of treatment, delays in time to treatment initiation can be seen as primarily policy related.
Direct-Acting Oral Anticoagulant Treatment for Acute Venous Thromboembolism
Although clinical trials are ongoing, the safety profile and net clinical benefit of DOACs for acute venous thromboembolism treatment are unclear.
Optimal Approaches to Treating Venous Thromboembolism in Patients With Cancer
Recent studies suggest that direct-acting oral anticoagulants may be a viable treatment option for cancer patients with VTE, but more research is needed.
Phase 2 Trial Examines Gene-Expression Profiling for Cancer of Unknown Primary Site
The study showed little value for the molecular assay in improving outcomes, but several weaknesses may have undermined the investigation.
Chemotherapy-Stimulated Immune Response: An Open Debate
Some chemotherapeutic drugs have been shown to stimulate the immune system, despite the historical belief that chemotherapies are immunosuppressive.
Dual Immunotherapy and an Emerging Biomarker in NSCLC
Data from a phase 2 trial of nivolumab + ipilimumab in NSCLC suggest that tumor mutational burden may be a superior biomarker to PD-L1 expression.
Want to read more?
Please login or register first to view this content.
